Latest Pharma and Biotech News
Pharmaceutical
3 June 2025 The UK risks losing £11 billion ($14 billion) in pharmaceutical R&D investment by 2033 unless urgent reforms are made to high and unpredictable clawback payments imposed on medicine sales to the National Health Service, according to a new report commissioned by the Association of the British Pharmaceutical Industry (ABPI).
Today's issue
Refine Search
Pharmaceutical
Italian drug discovery specialist Axxam and German AI firm Molecular Health have struck a strategic alliance aimed at improving the precision and speed of therapeutic target identification across multiple disease areas. 4 June 2025
Biotechnology
US clinical-stage biotech Vigil Neuroscience today announced a disappointing update on the Phase II IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). 4 June 2025
Pharmaceutical
Neuropsychiatric disorders specialist Alto Neuroscience, has entered into an asset purchase agreement with Chase Therapeutics Corporation to buy a portfolio of potentially best-in-class dopamine agonist drug combinations. 4 June 2025
Pharmaceutical
Danish dermatology specialist LEO Pharma has appointed Helle Hedegaard Juhl as executive vice president for global people and corporate affairs (GPCA). 4 June 2025
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published the UK’s first official guidance to support the safe development and use of phage therapies - treatments that use viruses to target and destroy harmful bacteria. 4 June 2025
Biotechnology
US clinical-stage biotech Sagimet Biosciences today reported denifanstat met all primary and secondary endpoints in a Phase III clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet’s license partner Ascletis Bioscience in China. 4 June 2025
Pharmaceutical
The European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal muscular atrophy (SMA), Swiss pharma giant Roche revealed today 4 June 2025
Pharmaceutical
The American medicines regulator has committed to reviewing the safety of the abortion pill mifepristone, amid renewed political scrutiny and pressure from conservative lawmakers. 4 June 2025
Pharmaceutical
US biotech BioAge Labs is expanding its obesity pipeline just months after shelving its lead drug in the category due to liver toxicity. 4 June 2025
Biotechnology
India’s Zydus Lifesciences announced that it has entered into a definitive agreement with Agenus to acquire India and Sri Lanka commercial rights for its investigational botensilimab (BOT) and balstilimab (BAL), combination therapy. 4 June 2025
Biotechnology
The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. 4 June 2025
Pharmaceutical
Sogroya (somapacitan injection) has been recommended by UK health technology assessor the National Institute for Health and Care Excellence (NICE) as a treatment for people aged 3 to 17 years with pediatric growth hormone deficiency, the UK subsidiary of Denmark’s Novo Nordisk revealed yesterday. 4 June 2025
Pharmaceutical
Sweden’s Karolinska Development today revealed that its portfolio company OssDsign has carried out a directed share issue through an accelerated book-building procedure that brought the company approximately 158 million kronor ($16.5 million). 4 June 2025
Pharmaceutical
US pharma major Eli Lilly has struck a deal worth up to $870 million with Swedish biotech Camurus, securing global rights to apply the latter’s extended-release delivery platform to a set of its own metabolic disease compounds. 4 June 2025
Pharmaceutical
The American medicines regulator has approved Bayer’s Nubeqa (darolutamide) for broader use in patients with metastatic castration-sensitive prostate cancer (mCSPC), marking a step forward for the drugmakeFood and Drug Administraton,r’s prostate cancer franchise. 4 June 2025
Pharmaceutical
The UK risks losing £11 billion ($14 billion) in pharmaceutical R&D investment by 2033 unless urgent reforms are made to high and unpredictable clawback payments imposed on medicine sales to the National Health Service, according to a new report commissioned by the Association of the British Pharmaceutical Industry (ABPI). 3 June 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved SFL Pharmaceuticals Deutschland’s Aumseqa (aumolertinib) for adults with non-small cell lung cancer (NSCLC). 3 June 2025
Pharmaceutical
Shares in MaaT Pharma, a French microbiome company in oncology, closed 25% higher Tuesday. 3 June 2025
Generics
German drugmaker STADA Arzneimittel has reported record earnings on revenues growth in its financial first quarter. 3 June 2025
Pharmaceutical
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 3 June 2025
All news
Pharmaceutical
Italian drug discovery specialist Axxam and German AI firm Molecular Health have struck a strategic alliance aimed at improving the precision and speed of therapeutic target identification across multiple disease areas. 4 June 2025
Biotechnology
US clinical-stage biotech Vigil Neuroscience today announced a disappointing update on the Phase II IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). 4 June 2025
Pharmaceutical
Neuropsychiatric disorders specialist Alto Neuroscience, has entered into an asset purchase agreement with Chase Therapeutics Corporation to buy a portfolio of potentially best-in-class dopamine agonist drug combinations. 4 June 2025
Pharmaceutical
Danish dermatology specialist LEO Pharma has appointed Helle Hedegaard Juhl as executive vice president for global people and corporate affairs (GPCA). 4 June 2025
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published the UK’s first official guidance to support the safe development and use of phage therapies - treatments that use viruses to target and destroy harmful bacteria. 4 June 2025
Biotechnology
US clinical-stage biotech Sagimet Biosciences today reported denifanstat met all primary and secondary endpoints in a Phase III clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet’s license partner Ascletis Bioscience in China. 4 June 2025
Pharmaceutical
The European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal muscular atrophy (SMA), Swiss pharma giant Roche revealed today 4 June 2025
Pharmaceutical
The American medicines regulator has committed to reviewing the safety of the abortion pill mifepristone, amid renewed political scrutiny and pressure from conservative lawmakers. 4 June 2025
Pharmaceutical
US biotech BioAge Labs is expanding its obesity pipeline just months after shelving its lead drug in the category due to liver toxicity. 4 June 2025
Biotechnology
India’s Zydus Lifesciences announced that it has entered into a definitive agreement with Agenus to acquire India and Sri Lanka commercial rights for its investigational botensilimab (BOT) and balstilimab (BAL), combination therapy. 4 June 2025
Biotechnology
The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. 4 June 2025
Pharmaceutical
Sogroya (somapacitan injection) has been recommended by UK health technology assessor the National Institute for Health and Care Excellence (NICE) as a treatment for people aged 3 to 17 years with pediatric growth hormone deficiency, the UK subsidiary of Denmark’s Novo Nordisk revealed yesterday. 4 June 2025
Pharmaceutical
Sweden’s Karolinska Development today revealed that its portfolio company OssDsign has carried out a directed share issue through an accelerated book-building procedure that brought the company approximately 158 million kronor ($16.5 million). 4 June 2025
Pharmaceutical
US pharma major Eli Lilly has struck a deal worth up to $870 million with Swedish biotech Camurus, securing global rights to apply the latter’s extended-release delivery platform to a set of its own metabolic disease compounds. 4 June 2025
Pharmaceutical
The American medicines regulator has approved Bayer’s Nubeqa (darolutamide) for broader use in patients with metastatic castration-sensitive prostate cancer (mCSPC), marking a step forward for the drugmakeFood and Drug Administraton,r’s prostate cancer franchise. 4 June 2025
Pharmaceutical
The UK risks losing £11 billion ($14 billion) in pharmaceutical R&D investment by 2033 unless urgent reforms are made to high and unpredictable clawback payments imposed on medicine sales to the National Health Service, according to a new report commissioned by the Association of the British Pharmaceutical Industry (ABPI). 3 June 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved SFL Pharmaceuticals Deutschland’s Aumseqa (aumolertinib) for adults with non-small cell lung cancer (NSCLC). 3 June 2025
Pharmaceutical
Shares in MaaT Pharma, a French microbiome company in oncology, closed 25% higher Tuesday. 3 June 2025
Generics
German drugmaker STADA Arzneimittel has reported record earnings on revenues growth in its financial first quarter. 3 June 2025
Pharmaceutical
Germany-based mental health specialist atai Life Sciences is to buy privately-held UK psychedelic drug developer Beckley Psytech in an all-share transaction subject to pre-agreed BPL-003 (mebufotenin benzoate) Phase IIb success criteria. 3 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze